Based on an investigation by the College of Medicine Investigation Committee (the COMIC) at The Ohio State University, and JEM’s review, JEM is issuing this Expression of Concern regarding Figures 1 E and 1 F from Pichiorri et al. (2013) J. Exp. Med. 210(5):951–68 and Correction Pichiorri et al. (2017) J. Exp. Med. 214(5):1557.
Vol. 210, No. 5 | https://doi.org/10.1084/jem.20120950 | April 22, 2013
Vol. 214, No. 5 | https://doi.org/10.1084/jem.2012095001172017c | January 19, 2017
Flavia
Pichiorri
, Dario
Palmieri
, Luciana
De Luca
, Jessica
Consiglio
, Jia
You
, Alberto
Rocci
, Tiffany
Talabere
, Claudia
Piovan
, Alessandro
Lagana
, Luciano
Cascione
, Jingwen
Guan
, Pierluigi
Gasparini
, Veronica
Balatti
, Gerard
Nuovo
, Vincenzo
Coppola
, Craig C.
Hofmeister
, Guido
Marcucci
, John C.
Byrd
, Stefano
Volinia
, Charles L.
Shapiro
, Michael A.
Freitas
, and Carlo M.
Croce
. 2013
. J. Exp. Med
. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
. 210
:951
–968
. https://doi.org/10.1084/jem.20120950Flavia
Pichiorri
, Dario
Palmieri
, Luciana
De Luca
, Jessica
Consiglio
, Jia
You
, Alberto
Rocci
, Tiffany
Talabere
, Claudia
Piovan
, Alessandro
Lagana
, Luciano
Cascione
, Jingwen
Guan
, Pierluigi
Gasparini
, Veronica
Balatti
, Gerard
Nuovo
, Vincenzo
Coppola
, Craig C.
Hofmeister
, Guido
Marcucci
, John C.
Byrd
, Stefano
Volinia
, Charles L.
Shapiro
, Michael A.
Freitas
, and Carlo M.
Croce
. 2017
. J. Exp. Med
. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
. 214
:1557
. https://doi.org/10.1084/jem.2012095001172017c© 2022 Rockefeller University Press
2022
This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
